

XanADu trial to be presented at global Alzheimer's conference

- **Professor Craig Ritchie, Chair of Xanamem Clinical Advisory Board, to provide study update on XanADu trial at CTAD**
- **CTAD, held from the 24th-27th October in Barcelona, is one of the leading conferences focused on Alzheimer's disease and the development of next generation treatments**
- **CTAD brings together worldwide leaders in the clinical development of Alzheimer's disease, and is an ideal forum to showcase Actinogen, and its XanADu trial of Xanamem in patients with mild Alzheimer's disease**

Sydney, 24 October 2018 - Actinogen Medical (ASX: ACW) is pleased to announce that Professor Craig Ritchie from the University of Edinburgh, will be presenting an update on XanADu, the Company's Phase II clinical trial of Xanamem in Alzheimer's disease, at the CTAD conference on October 26th.

Clinical Trials on Alzheimer's Disease (CTAD) is one of the most prestigious international conferences focused on Alzheimer's disease and development of next generation treatments. It is being held in Barcelona from the 24th-27th October.

Professor Craig Ritchie, Director of the Center for Dementia Prevention at The University of Edinburgh, and Chair of Actinogen's Xanamem Clinical Advisory Board, will provide an update on the XanADu trial. He will also present an overview of Actinogen's new and ongoing clinical studies, and potential new indications for Xanamem.

Actinogen continues to make excellent progress with its XanADu trial in Alzheimer's disease. A total of 171 patients are now enrolled, and as previously announced screening of potential patients for XanADu will cease on Friday 26 October. The final patient is expected to be enrolled within the next month and results from the study are anticipated during Q2 of 2019.


On behalf of the Company, Sarah Gregory PhD from the University of Edinburgh, will also present a scientific poster at CTAD, outlining her preliminary work in evaluating the role of cortisol in conditions that have potential for treatment with 11 β -HSD1 inhibitors, like Xanamem. Dr Gregory's work will assist the Company in defining the new potential indications to pursue in its expanded Xanamem clinical development program.

ENDS**Actinogen Medical**

Dr. Bill Ketelbey

CEO & Managing Director

P: +61 2 8964 7401

E: bill.ketelbey@actinogen.com.au @BillKetelbey**Investor and Media Enquiries**

Ben Walsh

WE Buchan

M: +61 411 520 012

E: bwalsh@we-buchan.com

About Actinogen Medical

Actinogen Medical (ASX: ACW) is an ASX-listed biotech company focused on innovative approaches to treating cognitive decline that occurs in chronic neurodegenerative and metabolic diseases. Actinogen Medical is developing its lead compound Xanamem, as a promising new therapy for Alzheimer's disease, a condition with a multibillion-dollar market potential. In the US alone, the cost of managing Alzheimer's disease is estimated to be US\$250bn, and is set to increase to US\$2tn by 2050, outstripping the treatment costs of all other diseases. Alzheimer's disease is now the leading cause of death in the UK and second only to ischaemic heart disease in Australia

About Xanamem™

Xanamem's novel mechanism of action sets it apart from other Alzheimer's treatments. It works by blocking the excess production of cortisol - the stress hormone – through the inhibition of the 11β-HSD1 enzyme in the brain. This enzyme is highly concentrated in the hippocampus and frontal cortex, the areas of the brain most affected by Alzheimer's disease. There is a strong association between chronic stress and excess cortisol that leads to changes in the brain affecting memory, and to the development of amyloid plaques and neural death – all hallmarks of Alzheimer's disease.

About XanADu

XanADu is a Phase II double-blind, 12-week, randomised, placebo-controlled study to assess the safety, tolerability and efficacy of Xanamem in subjects with mild dementia due to Alzheimer's disease. XanADu, is enrolling 174 patients at 25 research sites across Australia, the UK and the USA. Enrolment is expected to complete in Q4 2018, with top-line results expected in Q2 2019. The trial is registered on www.clinicaltrials.gov with the identifier: NCT02727699, where more details on the trial can be found, including the study design, patient eligibility criteria and the locations of the study sites.

Actinogen Medical encourages all current investors to go paperless by registering their details with the designated registry service provider, Link Market Services.